Ibogaine treatment for San Francisco residents: the physician-prescribed pathway through Brazil

Ibogaine is a Schedule I controlled substance in the United States. No clinic, hospital, or physician in California can legally prescribe or administer it. That policy gap is not closing soon, even as Sacramento has taken meaningful steps to enable research.

In October 2025, Governor Gavin Newsom signed AB 1103 (Chapter 571), which streamlines the state Research Advisory Panel's review of federally authorized clinical studies involving Schedule I and II substances, including ibogaine. The bill took effect January 1, 2026. It enables research, not treatment. No California resident can legally receive ibogaine inside the United States as of June 2026.

San Francisco's overdose trajectory makes the stakes visible. Deaths soared to a record 810 in 2023 before falling to 633 in 2024 — nine consecutive months of year-over-year declines. Fentanyl remains the primary driver: involved in more than 70% of accidental deaths, often combined with methamphetamine or cocaine. Fatal overdose rates among Black residents are several times higher than among other demographic groups — a disparity that mirrors national trends and concentrates the crisis in neighborhoods like the Tenderloin and SOMA.

San Francisco has invested heavily in harm reduction — naloxone distribution, expanded buprenorphine and methadone access, contingency management for stimulant use. Those investments contributed to the 2024 decline. They do not reach everyone. For San Francisco families who have exhausted local options, the physician-prescribed pathway runs through Brazil.

If your loved one is in active addiction, you have probably heard a lot of clinical language that did not translate into results. Ibogaine is worth understanding differently, because it works differently.

Ibogaine is a naturally occurring compound derived from the root bark of the iboga plant. It acts on multiple receptor systems simultaneously, including opioid receptors, NMDA receptors, and serotonin pathways. The result, for many patients, is a dramatic reduction in acute opioid withdrawal symptoms and a reset of the neurological patterns that drive compulsive use. The full receptor-level mechanism is covered in detail on our ibogaine overview.

What makes ibogaine different from medication-assisted treatment goes beyond pharmacology. It is the window that opens after. In the weeks following a session, the brain enters a period of elevated neuroplasticity, sometimes called the Window of Wonder, that typically lasts 2 to 12 weeks. This is not a passive recovery period. It is the window that Nekawa's 15-day on-site integration and 45-day at-home coursework are specifically built around, because what a student does during that window shapes what the session becomes long-term.

Ibogaine is not appropriate for everyone. The peer-reviewed research is serious and growing, and so is the understanding of who is and is not a candidate. Cardiac history, current medications, and other health factors all matter. That is precisely why the physician-prescribed pathway requires a full medical workup before any session proceeds.

The ibogaine session at the heart of Nekawa's program is prescribed and administered by independent licensed Brazilian physicians, not by Nekawa. Understanding what that means in practice matters, because it is the difference between a supervised medical procedure and an unmonitored retreat experience.

Before the prescribing physicians clear a patient for ibogaine, the workup includes:

• EKG
• QT-interval check
• Comprehensive blood panel
• Liver function test
• Magnesium loading

The QT-interval check is the critical cardiac screen. Ibogaine affects cardiac conduction, and a prolonged QT interval is a contraindication. This is not a formality. It is the reason the medical workup exists.

During the session, an on-site physician is present throughout. The hospital's ICU-trained nursing team monitors continuous cardiac telemetry for a minimum of 24 hours post-dose. The session itself moves through distinct phases: the intense visionary phase lasts 6 to 12 hours, followed by roughly 12 hours of quieter mental processing, then 24 to 48 hours of physical recuperation.

Nekawa's role is not clinical. We build the preparation, the environment, and the integration structure around the medical team's work. The full program structure is:

• 10 days of preparation and on-site medical onboarding before the session
• The ibogaine session, administered by the medical team in a hospital setting with continuous cardiac telemetry
• 15 days of structured integration on the property
• 45 days of at-home integration coursework after returning home

Longer on-site programs of up to 90 days are available for students who want deeper transformation work. The 28-day structure is the foundation; the extended program builds on it.

See our cardiac safety overview for the full QT-interval, EKG, and screening protocol the prescribing physicians follow.

Mexico and Costa Rica have become common destinations for ibogaine, and some of the programs there are run by serious people. But the regulatory framework is not the same, and that difference matters when you are talking about a compound that requires continuous cardiac monitoring.

In Brazil, ibogaine is approved for medical use under ANVISA, Brazil's federal health agency, the equivalent of the FDA. Treatment is prescribed by licensed physicians and delivered within hospital infrastructure that includes emergency response capability. This is not a private villa. It is not a retreat center operating in a gray area. The current US and global legal status of ibogaine makes clear why the structure of the Brazilian system is distinct.

Nekawa is a wellness education academy, structured around the hospital infrastructure that physician-administered ibogaine treatment requires. We do not run the medical protocol. The prescribing physicians do. What we provide is the preparation curriculum, the environment, the integration coursework, and the program structure that gives the medical session its full context.

The distinction matters for San Francisco students specifically. The Bay Area has been at the center of psychedelic policy conversations for years — from decriminalization efforts to clinical research at UCSF. But hospital-administered ibogaine with continuous cardiac telemetry is a different category of care than an underground session or an unregulated retreat. That is what the Brazilian pathway provides.

San Francisco International (SFO) connects to São Paulo–Guarulhos (GRU) or Rio de Janeiro–Galeão (GIG) via one-stop service through Houston, Atlanta, or Dallas. Some carriers offer seasonal nonstop service to GRU. Total travel time typically runs 14 to 18 hours door to door, depending on connection length.

From either GRU or GIG, it is a 4-hour drive along the BR-101 coastal highway to Paraty, on Brazil's Costa Verde coast. We arrange private ground transport from the airport, so students arrive directly without navigating Brazilian transit or making connections.

What you arrive to is not a medical facility. Our location sits in the Atlantic rainforest, the Mata Atlântica, at the edge of the sea. Old-growth jungle. Waterfalls. A protected lagoon. A bay scattered with more than 300 forested islands. The colonial port town of Paraty is just outside. The environment is part of the program. The preparation and integration work we walk students through is designed to use the setting intentionally.

As of January 1, 2026, US travelers need an approved Brazilian eVisa to enter Brazil. Apply online at brazil.vfsevisa.com.

• Cost: US$80.90
• Processing time: about 72 hours
• Validity: 10 years, multiple entries of up to 90 days per stay
• Passport: US passport with at least 6 months of remaining validity

Our intake team walks every student through this during onboarding.

California is among the most active states in ibogaine policy — but active does not mean accessible.

AB 1103, signed in October 2025, streamlines the Research Advisory Panel review process for FDA-authorized studies involving Schedule I and II substances. AB 2489 further authorizes the panel to submit FDA applications for multisite clinical trials of ibogaine among veteran subjects with suicidality-related comorbidities. The April 2026 Executive Order on ibogaine research matters in a city with a substantial VA presence and veteran population.

San Francisco's own psychedelic policy history is relevant context. State Senator Scott Wiener proposed psychedelic-assisted therapy legislation after Governor Newsom vetoed a decriminalization bill in 2023, asking lawmakers to focus on therapeutic frameworks first. AB 1103 represents that narrower research-enabling approach — but it is not treatment access. California's posture is research-enabling rather than research-funding, unlike Texas's $50 million SB 2308 program.

For a San Francisco resident in active addiction in June 2026, the practical reality is unchanged: no California provider can prescribe or administer ibogaine, and no domestic clinical trial pathway is available as a treatment option. California recorded 7,385 provisional drug overdose deaths in 2024 per CDC NCHS data. For now, the physician-prescribed pathway runs through Brazil.

The ibogaine session is not the end of the program. It is closer to the beginning of the part that requires the most work.

The 45 days of at-home integration coursework that follow the on-site program are structured around the Window of Wonder, the 2 to 12 weeks of elevated neuroplasticity that follow the session. This is when the brain is most receptive to new patterns, and it is when the coursework is designed to be used. Students returning to San Francisco — to a flat in the Mission, a room in the Richmond, or a condo in Nob Hill — return to the same environment where the patterns formed. The at-home coursework is built with that reality in mind, including the social networks, housing instability, and triggers that make recovery in this city its own challenge.

San Francisco's expanded naloxone distribution and MAT enrollment contributed to the 2024 decline in overdose deaths. Integration is the complement on the other side of a medical session: structured reflection, specific practices, and ongoing engagement with the material from the preparation phase. Our team remains in contact with students through this period. The work continues.

For students with opioid dependence specifically, the opioid program page covers how the full curriculum is structured for that context. Students navigating burnout, depression, or anxiety alongside addiction may find the burnout and mental health program relevant as well.

The first step is a discovery call. This is a candidacy and program-fit conversation, not a sales call. We are looking at whether Nekawa's program is genuinely right for you or your loved one, and whether you are ready to do what the program requires.

On the call, we cover the program structure, the preparation curriculum, what the on-site experience involves, and what the at-home integration period looks like. We also talk honestly about who the program is not right for. Clinical screening is conducted separately by the prescribing physicians. What we assess is program fit, commitment, and readiness.

If the program is a fit, we move to intake, onboarding, and scheduling. Our intake team handles visa guidance, ground transport coordination, and preparation coursework. You do not navigate this alone.

To start, visit Book a discovery call. If you are a San Francisco family member trying to understand whether this is the right path, the discovery call is the right place to begin.